What is LL-37? The antimicrobial peptide with barely any human evidence

LL-37 shows up in immune-support stacks and nasal sprays, usually paired with Thymosin Alpha-1 under names like "Immune Defense Spray." The pitch sounds specific: an antimicrobial peptide your own body already makes. The evidence behind that pitch is thinner than the marketing suggests.

What LL-37 actually is

LL-37 is the active fragment of human cathelicidin, the only cathelicidin-type antimicrobial peptide the human body produces. It's the piece sold commercially, as an injectable (5 mg vials) or as a nasal spray, usually bundled with Thymosin Alpha-1 in the same "Immune / Gut" product category.

Our own compound reference tags LL-37 as antimicrobial and immune defense with very limited human work: evidence tier [weak], cathelicidin-derived, preclinical. In the tiering framework we use across this site, [weak] means animal data or in-vitro plausibility, maybe a small case series. A promising signal, not enough humans yet. That's the honest state of the evidence, full stop.

Why the mechanism story outruns the proof

LL-37 keeps showing up in immune stacks because the mechanism is genuinely interesting. It's a real antimicrobial peptide, not a marketing invention. That's exactly the trap this category falls into over and over: a credible mechanism gets marketed as if the mechanism itself were the proof. Mechanism plausibility and human outcome data are two different things, and LL-37 sits almost entirely on the mechanism side of that line.

This is the same gap we flagged with SS-31: a strong mechanism story, where the population and evidence tier the mechanism was actually tested in matters more than the story itself. With LL-37 there isn't even a narrow clinical population to point to the way SS-31 has its mitochondrial myopathy trials. The wiki's own tier for LL-37 sits one step further back: preclinical, not "narrow human trial."

What that means if you're considering it

Nothing here means LL-37 does nothing. Cathelicidins are a real, well characterized part of innate immune defense. What it means is that if you're buying a product that names LL-37 for immune support, you're buying ahead of the human evidence, not on top of it. That's worth comparing to other compounds sold in the same "Immune / Gut" bracket, like KPV, where the regulatory and evidence picture is at least documented enough to track. LL-37 doesn't have that trail yet in what we've reviewed.

Before paying for any immune peptide, the question worth asking a seller is simple: what evidence tier is this actually at, and do they say so, or do they let the mechanism do the selling? See how to vet a peptide seller for the general version of that check. The full Ouros Lab blog tracks compounds like this one by one, tier by tier.

FAQ

What is LL-37 exactly?

LL-37 is the active peptide fragment of human cathelicidin, the only cathelicidin-type antimicrobial peptide people produce naturally. It's sold commercially, usually as an injectable or a nasal spray paired with Thymosin Alpha-1.

Is there human clinical data on LL-37?

Very little. Our own compound reference grades it [weak], meaning the evidence is preclinical: animal or in-vitro work, not established human trials.

Why do sellers market LL-37 for immune support?

Because the underlying biology, a natural antimicrobial peptide involved in innate immune defense, is real and easy to explain. That mechanism story is being sold ahead of the human evidence, not on top of it.

How is LL-37 different from more established immune peptides like Thymosin Alpha-1?

Thymosin Alpha-1 carries [moderate] evidence, including approval abroad for thymic-deficiency treatment and use as a hepatitis and cancer adjuvant. LL-37 sits at [weak], preclinical. They're often sold together, but they are not at the same evidence tier.